文章摘要

乳腺钼靶联合超声和CA153、CEA、CA125在早期乳腺浸润性导管癌中的应用

作者: 1王志清, 1黄莉, 2张建国, 1陈亚明
1 安徽皖北煤电集团总医院影像科,安徽 宿州 234000
2 安徽皖北煤电集团总医院超声科,安徽 宿州 234000
通讯: 王志清 Email: wzqct@sina.com
DOI: 10.3978/j.issn.2095-6959.2021.03.010

摘要

目的:探究乳腺钼靶联合超声以及血清糖链抗原153(carbohydrate antigen 153,CA153)、血清癌胚抗原(carcinoembryonic antigen,CEA)、血清糖链抗原125(carbohydrate antigen 125,CA125)在诊断早期乳腺浸润性导管癌中的应用价值,为患者的临床诊断提供指导。方法:选择2017年2月至2019年7月皖北煤电集团总医院收治的60例早期乳腺浸润性导管癌患者作为观察组,另选择同期皖北煤电集团总医院收治的60例良性乳腺肿块患者作为对照组。对比两组患者的乳腺钼靶和超声的影像学特征以及血清CA153、CEA和CA125阳性率,同时对乳腺钼靶、超声和肿瘤标志物检测及3项联合在早期乳腺浸润性导管癌中的诊断效能进行比较。结果:两组患者在乳腺钼靶和超声上均有典型性特征,差异有统计学意义(P<0.05)。观察组患者的血清CA153、CEA和CA125阳性检出率均明显高于对照组,差异有统计学意义(P<0.05)。三项联合检查在诊断早期乳腺浸润性导管癌中的敏感度、准确度和阴性预测值分别为93.33%、88.33%和92.59%,均明显高于乳腺钼靶、乳腺超声和肿瘤标志物检测(分别为73.33%、74.17%、73.77%;76.67%、77.50%、7.05%;70.00%、72.50%、71.43%),差异有统计学意义(P<0.05)。三项联合检查的特异度(83.33%)、阳性预测值(84.85%)与乳腺钼靶、乳腺超声和肿瘤标志物检测(分别为75.00%、78.83%、75.00%和74.58%、77.97%、73.68%)比较,差异无统计学意义(P>0.05)。结论:乳腺钼靶联合超声和血清CA153、CEA、CA125检测能够有效提高早期乳腺浸润性导管癌的诊断准确率,对其早期诊治具有重要意义。
关键词: 乳腺浸润性导管癌;乳腺钼靶;超声检查;糖链抗原153;癌胚抗原

Application of mammography combined with ultrasound and CA153, CEA, CA125 in early-stage invasive ductal carcinoma of breast

Authors: 1WANG Zhiqing, 1HUANG Li, 2ZHANG Jianguo, 1CHEN Yaming
1 Department of Imaging, Anhui Wanbei Coal and Electricity Group General Hospital, Suzhou Anhui 234000, China
2 Department of Ultrasound, Anhui Wanbei Coal and Electricity Group General Hospital, Suzhou Anhui 234000, China

CorrespondingAuthor: WANG Zhiqing Email: wzqct@sina.com

Abstract

Objective: To research the clinical application of mammography combined with ultrasonography and serum carbohydrate antigen 153 (CA153), serum carcinoembryonic antigen (CEA), serum carbohydrate antigen 125 (CA125) in the diagnosis of early-stage invasive ductal breast carcinoma. Methods: From February 2017 to July 2019, 60 patients with early-stage invasive ductal breast carcinoma were selected as a observation group, and 60 cases patients with benign breast masses were selected as a control group. The imaging features of mammography and ultrasound, as well as the positive rates of serum CA153, CEA and CA125 were compared between the 2 groups. Meanwhile, the diagnostic efficacy of mammography, ultrasound, tumor markers detection and the combination of the three in the diagnosis of early-stage invasive ductal breast carcinoma were compared. Results: Both groups had typical characteristics in mammography and breast ultrasound, and the difference was statistically significant (P<0.05). The detection rates of positive serum CA153, CEA and CA125 were significantly higher in the observation group than in the control group, and the differences were statistically significant (P<0.05). The sensitivity, accuracy and negative predictive value of the three combined examinations in the diagnosis of early-stage invasive ductal breast carcinoma were 93.33%, 88.33% and 92.59%, respectively, which were significantly higher than those of mammography, breast ultrasound and tumor markers detection (73.33%, 74.17%, 73.77%; 76.67%, 77.50%, 77.05%; 70.00%, 72.50%, 71.43%, respectively), and the differences were statistically significant (P<0.05). The specificity (83.33%) and positive predictive value (84.85%) of the three combined examinations were not statistically significant (P>0.05) compared with those of mammography, breast ultrasound and tumor marker testing (75.00%, 78.83%, 75.00% and 74.58%, 77.97%, 73.68%, respectively). Conclusion: Mammography combined with ultrasound and serum CA153, CEA, CA125 can effectively improve the diagnostic accuracy of early-stage invasive ductal breast carcinoma, which is of great significance for its early diagnosis and treatment.
Keywords: invasive ductal breast carcinoma; mammography; ultrasonography; carbohydrate antigen 153; carcinoembryonic antigen